Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens

被引：37
|
作者：
Bonomo, Robert A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Vet Affairs Med Ctr, Med Serv, Louis Stokes Cleveland Dept, 10701 East Blvd, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA
[5] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ, Dept Prote & Bioinformat, Cleveland, OH 44106 USA
[7] CWRU Cleveland VAMC Case VA CARES, Cleveland, OH USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷
关键词：
cefiderocol; cephalosporin; carbapenem-resistant Enterobacteriaceae; nonfermenting gram-negative bacteria; siderophore; GRAM-NEGATIVE PATHOGENS; LACTAMASE INHIBITOR; MULTIDRUG-RESISTANT; BACTERIA;
D O I：
10.1093/cid/ciz823
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a "Trojan horse" active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases.
引用
收藏
页码：519 / 520
页数：2
相关论文
共 50 条
  • [31] Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
    Mabayoje, Diana A.
    NicFhogartaigh, Caoimhe
    Cherian, Benny P.
    Tan, Mei Gie Meiqi
    Wareham, David W.
    JAC-ANTIMICROBIAL RESISTANCE, 2021, 3 : 21 - 24
  • [32] Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A case report
    Finch, Natalie A.
    Granillo, Alejandro
    Pouya, Nazanin
    Bhimraj, Adarsh
    Miller, William R.
    Tam, Vincent H.
    PHARMACOTHERAPY, 2025, 45 (01): : 66 - 69
  • [33] In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
    Kohira, Naoki
    West, Joshua
    Ito, Akinobu
    Ito-Horiyama, Tsukasa
    Nakamura, Rio
    Sato, Takafumi
    Rittenhouse, Stephen
    Tsuji, Masakatsu
    Yamano, Yoshinori
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (02) : 729 - 734
  • [34] Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa
    Ghazi, Islam M.
    Monogue, Marguerite L.
    Tsuji, Masakatsu
    Nicolau, David P.
    PHARMACOLOGY, 2018, 101 (5-6) : 278 - 284
  • [35] Role of β-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species
    Mezcord, Vyanka
    Wong, Olivia
    Pasteran, Fernando
    Corso, Alejandra
    Tolmasky, Marcelo E.
    Bonomo, Robert A.
    Ramirez, Maria Soledad
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 61 (01)
  • [36] Activity of cefiderocol in combination with tetracycline analogues against carbapenem-resistant Acinetobacter baumannii
    Yin, Yuhan
    Xu, Na
    Wang, Xinjie
    JOURNAL OF ANTIBIOTICS, 2025, 78 (03): : 190 - 196
  • [37] Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model
    Ghazi, Islam M.
    Monogue, Marguerite L.
    Tsuji, Masakatsu
    Nicolau, David P.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 51 (02) : 206 - 212
  • [38] Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA
    Huang, En
    Thompson, Rebekah N.
    Moon, Sun Hee
    Keck, Jacob M.
    Lowry, Michael S.
    Melero, Joe
    Jun, Se-Ran
    Rosenbaum, Eric R.
    Dare, Ryan K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (07) : e0029024
  • [39] Challenges Facing Two Outbreaks of Carbapenem-Resistant Acinetobacter baumannii: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants
    Rodriguez-Aguirregabiria, Montserrat
    Lazaro-Perona, Fernando
    Cacho-Calvo, Juana Begona
    Arellano-Serrano, Ma Soledad
    Ramos-Ramos, Juan Carlos
    Rubio-Mora, Eduardo
    Diaz-Almiron, Mariana
    Asensio-Martin, Ma Jose
    ANTIBIOTICS-BASEL, 2024, 13 (08):
  • [40] ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
    Jacobs, Michael R.
    Abdelhamed, Ayman M.
    Good, Caryn E.
    Rhoads, Daniel D.
    Hujer, Kristine M.
    Hujer, Andrea M.
    Domitrovic, T. Nicholas
    Rudin, Susan D.
    Richter, Sandra S.
    van Duin, David
    Kreiswirth, Barry N.
    Greco, Chris
    Fouts, Derrick E.
    Bonomo, Robert A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (01)
12345